Public consultation has begun on the revised Compounding Standard, as part of the wider review of the Professional Practice Standards developed by PSA

The Standard outlines the actions pharmacists need to meet to enable patients to have timely access to safe, efficacious and quality compounded medicines.

One of the major outcomes of the review has been to ensure consistency of the Compounding Standard with the Pharmacy Board of Australia’s Guidelines on compounding of medicines, particularly with respect to the differentiation between simple and complex compounding activities.

While the Standard is intended to apply to all compounding, it identifies additional actions that need to be undertaken when compounding complex preparations. The review also highlighted the requirement for compounding activities to be guided by appropriate risk assessment.

During the consultation period on the revised Compounding Standard, PSA welcomes comments from interested individuals and organisations, including members of the pharmacy profession as well as consumers, other health professional groups and practitioners, educators, researchers and government bodies.

The consultation paper, including the revised Compounding Standard and accompanying risk assessment tool, can be accessed here.

PSA says it acknowledges the Australian Government Department of Health for providing funding for this important work as part of the Pharmaceutical Benefits Scheme Access and Sustainability Package, including the Sixth Community Pharmacy Agreement.

Please review the consultation paper first then provide feedback through the consultation survey, which can be found here.

Consultation on the revised Compounding Standard will be open until 18 April 2017.

Any queries about this process can be sent to policygrp@psa.org.au